HBP、SAA、nCD64在颅内感染早期诊疗中作用的研究进展  

Research progress on the role of HBP,SAA,and nCD64 in the early diagnosis and treatment of intracranial infection

作　　者：赵亚宁 胡涛[1] 王一鸣 任子阳 陈胜利[1] ZHAO Yaning;HU Tao;WANG Yiming;REN Ziyang;CHEN Shengli(Department of Neurosurgery of the Fifth Clinical Medical College,Shanxi Medical University,Taiyuan 030012,Shanxi,China)

机构地区：[1]山西医科大学第五临床医学院神经外科,山西太原030012

出　　处：《中南医学科学杂志》2024年第4期685-688,共4页Medical Science Journal of Central South China

基　　金：山西省医学重点科研项目(2023XM030);山西省基础研究计划项目(202203021211057)。

摘　　要：开颅术后颅内感染是神经外科的严重并发症,其致残、致死率均较高。临床常规检测颅内感染指标的特异性、敏感性不足,脑脊液细菌培养耗时且阳性率低。近年来,肝素结合蛋白(HBP)、血清淀粉样蛋白A(SAA)、中性粒细胞CD64(nCD64)作为新型感染标志物,在敏感性、特异性方面具有独特优势,并且检测方法简便快捷,在感染诊断、疗效评估、预后判断等方面具有广泛的临床应用前景。本文从HBP、SAA、nCD64在颅内感染早期中的诊断价值、临床应用及检测方法等方面进行综述。Post-craniotomy intracranial infection is a serious complication in neurosurgery,with high rates of disability and mortality.The specificity and sensitivity of routine clinical detection of intracranial infection indicators were insufficient,and cerebrospinal fluid bacterial culture was time-consuming and had a low positive rate.In recent years,heparin binding protein(HBP),serum amyloid A(SAA),and neutrophil CD64 have unique advantages in sensitivity and specificity as novel infection markers,and their detection methods were simple and fast.They have broad clinical application prospects in infection diagnosis,efficacy evaluation,prognosis judgment,and other aspects.This article reviews the diagnostic value,clinical application,and detection methods of HBP,SAA,and nCD64 in the early stage of intracranial infection.

关 键 词：肝素结合蛋白 血清淀粉样蛋白A 中性粒细胞CD64 颅内感染 早期诊疗 

分 类 号：R651[医药卫生—外科学]